Phaseline

Companies › Domain Therapeutics Australia

Domain Therapeutics Australia: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DT-7012
anti-CCR8 monoclonal antibody
CCR8Phase 1Advanced Solid TumorsSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06819735DT-7012Phase 1Advanced Solid TumorsOncologySep 2027

Targets

CCR8 (1)

Companies with the same targets

Takeda LaNova Medicines Bristol-Myers Squibb Bayer

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.